Mesoblast Ltd (MESO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Mesoblast Ltd stock (MESO) is currently trading at $15.65. Mesoblast Ltd PS ratio (Price-to-Sales) is 31.76. Analyst consensus price target for MESO is $35.00. WallStSmart rates MESO as Sell.
- MESO PE ratio analysis and historical PE chart
- MESO PS ratio (Price-to-Sales) history and trend
- MESO intrinsic value — DCF, Graham Number, EPV models
- MESO stock price prediction 2025 2026 2027 2028 2029 2030
- MESO fair value vs current price
- MESO insider transactions and insider buying
- Is MESO undervalued or overvalued?
- Mesoblast Ltd financial analysis — revenue, earnings, cash flow
- MESO Piotroski F-Score and Altman Z-Score
- MESO analyst price target and Smart Rating
Mesoblast
📊 No data available
Try selecting a different time range
Smart Analysis
Mesoblast Ltd (MESO) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Mesoblast Ltd (MESO) Key Strengths (1)
Revenue surging 458.60% year-over-year
Supporting Valuation Data
Mesoblast Ltd (MESO) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 31.8x annual revenue
Very low institutional interest at 2.54%
Premium pricing at 3.5x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Mesoblast Ltd (MESO) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 458.60%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (31.76), Price/Book (3.51) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -19.00%, Operating Margin at -302.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -19.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 458.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MESO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MESO's Price-to-Sales ratio of 31.76x trades at a deep discount to its historical average of 98.5x (20th percentile). The current valuation is 93% below its historical high of 437.79x set in Jan 2025, and 157% above its historical low of 12.36x in Jul 2016. Over the past 12 months, the PS ratio has compressed from ~263.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Mesoblast Ltd (MESO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Mesoblast Ltd is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 17M with 459% growth year-over-year.
Key Findings
Revenue growing at 459% YoY, reaching 17M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 41% of revenue (7M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -16M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Mesoblast Ltd maintain 459%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Mesoblast Ltd.
Bottom Line
Mesoblast Ltd is a high-conviction growth story with revenue accelerating at 459% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 4:51:22 PM
About Mesoblast Ltd(MESO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.